Novartis Q4 earnings beat estimates with sales up 16%, driven by strong demand for Entresto, Kesimpta, and Cosentyx. CEO Narasimhan reportedly downplays Entresto's U.S. patent expiration ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth. After signing 30 deals ...

The Galaxy S-series phones have always been special in every aspect. Needless to say, these phones look premium and to make them look stand out, Samsung packs the Galaxy S-series phones with ...

Novartis AG’s plan to sell its 70.6% stake in Novartis India is on track, CEO Vas Narasimhan confirmed at the World Economic Forum in Davos. Speaking to CNBC-TV18, he emphasised the company’s ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

A Google parent-owned startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end, marking a significant milestone in pharmaceutical development as ...

We advise you to avoid simply saving the image previews you see below. These wallpaper previews are compressed and optimized for improved website performance. Instead, you should click the button ...

Greece on Monday prosecuted a pair of protected witnesses for alleged perjury in a long-running bribery probe involving the Swiss pharmaceutical firm Novartis, a justice source said. The man and woman ...

Novartis won an order from a U.S. appeals court in Washington on Thursday temporarily blocking MSN Pharmaceuticals from launching a generic version of Novartis' heart-failure drug Entresto, per a ...

TIN-816 is under clinical development by Novartis and currently in Phase II for Sepsis. According to GlobalData, Phase II drugs for Sepsis have a 50% phase transition success rate (PTSR) indication ...

Entresto’s importance to Novartis is illustrated in the company’s most recent quarterly report, which revealed that the drug generated $5.6 billion in the first three quarters of 2024 ...

Novartis is locked in a legal back-and-forth with MSN Pharma over alleged patent infringement of its heart failure drug Entresto. Novartis on Thursday secured a last ...